Introduction {#s1}
============

Gastric cancers are highly lethal malignancies with five-year survival rates being one of the worst reported for any solid tumors. According to data from the National Cancer Institute Surveillance, Epidemiology and End [Results](#s3){ref-type="sec"} (SEER) Program, the five-year survival for patients with gastric cancer (GC) improved only modestly over the last 50 years, from 12 to 22 percent [@pone.0090133-Levi1]. The propensity of GC for early metastatic dissemination has been well documented in previous studies [@pone.0090133-Folli1], [@pone.0090133-Nigro1]. Based on the recent adjuvant phase III trials, survival benefit from adjuvant chemotherapy or chemoradiation therapy has been documented in GC [@pone.0090133-Bang1]--[@pone.0090133-Macdonald1]. However, 25 to 40% of all surgically resected GC patients still develop recurrences that are not amenable to re-resection [@pone.0090133-Bang1], [@pone.0090133-Macdonald1]--[@pone.0090133-Lee2]. For pathologic stage III and IV GC, 5-year disease-free survival rates are very poor (stage IIIA, 57.6%, stage IIIB, 39.6%; and stage IV 26.3%) [@pone.0090133-Kim1] implicating that these tumors have inherently aggressive behaviour. In contrast, pathologic stage II GC patients have more favorable clinical outcome with 5-year disease free survival rates of 76% −90% following surgery and adjuvant treatment [@pone.0090133-Kim1], [@pone.0090133-Lee2]. Nevertheless, there is a wide spectrum of clinical aggressiveness even within the same stage with some patients being cured with surgery alone while some patients recur shortly after surgery and adjuvant chemoradiation therapy. Hence, based on the hypothesis that there is a significant molecular heterogeneity, we designed a large-scaled gene expression profiling study to develop a molecular test which may efficiently discriminate low-risk from high-risk GC groups for recurrence after surgery.

A molecular test that identifies high-risk patients for recurrence may lead to optimized perioperative treatment strategies in GC. The discovery phase included GC patients from all clinical stages treated with chemoradiotherapy (N = 520). Tumor blocks from these patients were subjected to prognostic gene discovery using Whole Genome DASL assay (WG-DASL) (Illumina, San Diego, CA), a microarray gene expression profiling method for formalin-fixed paraffin-embedded tissue (FFPE). The purpose was to develop hypothesis for clinical utility and discover candidate prognostic or internal reference genes that will help design focused gene expression assay. Results from this phase suggested that clinical utility of a gene expression based prognostic algorithm may potentially distinguish a high-risk group among stage II patients.

The objective of the project was to develop a hypothesis with clinical utility and discover candidate prognostic or internal reference genes in order to design focused gene expression assays. The results from the discovery phase suggest that clinical utility of a gene expression-based prognostic algorithm may potentially distinguish a high-risk group among stage II patients. With the use of a robust multistep prognostic algorithm, Gastric Cancer Prognostic Score (GCPS) for stage II GC patients was developed to identify high-risk patients for recurrence after surgery.

Methods {#s2}
=======

From September 1994 to December 2005, 1,557 GC patients underwent curative gastrectomy at Samsung Medical Center. Among those, 1,107 patients were selected based on following criteria: histologically confirmed adenocarcinoma of the stomach; surgical resection of tumour without macroscopic or microscopic residual disease; age ≥18; pathology stage IB (T2bN0, T1N1 but not T2aN0) to IV, according to the American Joint Committee on Cancer (AJCC) staging system (6^th^ Ed); complete surgical record and treatment record, and patients receiving the INT-0116 regimen as adjuvant treatment [@pone.0090133-Macdonald1]. The study was approved by the institutional review board of the Samsung Medical Center, Seoul, South Korea (IRB approval number: SMC 2010-10-025). All study participants provided written informed consent form recommended by the IRB. In the patients who have deceased at the time of study entry, written informed consent forms were waived by the IRB. Study design and patient cohorts are provided according to REMARK guideline ([**Figure 1A, 1B**](#pone-0090133-g001){ref-type="fig"}, **[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 1**). Of the cohort of 1,107 patients, a discovery set of 520 patients and a validation set of 587 patients were randomly assigned and allocated to 6 batches stratified by tumor size and year of surgery for WG-DASL assay.

![The Consort Diagram.\
(A) A multi-step approach gene expression profiling design, (B) Consort Diagram.](pone.0090133.g001){#pone-0090133-g001}

To avoid false-positive conclusions due to over-fitting, prognostic algorithms and their predefined cut-points were tested in independent cohorts that were not used for prognostic gene discovery and algorithm building. A 4-phase study was designed, with 4 pre-defined independent cohorts recruited from the Samsung Medical Center. The first 3 cohorts include patients with similar clinical and pathological features from chemoradiotherapy-treated study cohorts (**[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 2**). The **first phase (discovery phase)** of the study included GC patients from all clinical stages who were treated with chemo-radiotherapy (N = 520) [@pone.0090133-Kim1]. Tumor blocks from these patients were subjected to prognostic gene discovery using the WG-DASL (Illumina, San Diego, CA), a microarray gene expression profiling method for FFPE [@pone.0090133-Macdonald1]. An ad-hoc external validation of the gene set was performed to minimize any bias from single institutional cohort. The **second phase (algorithm development)** was to translate findings from the first phase into a clinically applicable test format. We chose the nCounter platform (Nanostring Technologies, Seattle, WA), because of its ability to interrogate the expression levels of up to 800 genes using total RNA extracted from FFPE in a single-tube reaction [@pone.0090133-Kim1]. We screened stage II patients from the first phase (N = 186) for *de novo* discovery of prognostic genes, selected ideal combinations of genes using the gradient least absolute shrinkage and selection operator (LASSO) algorithm [@pone.0090133-Sohn1], and then built a first-generation GCPS (GCPS-g1) by adding the products of normalized gene expression and coefficients from the Cox model for DFS. In the **third** cohort of stage II patients (N = 216). In the **fourth phase (testing of clinical utility in a surgery-only setting)**, we tested the potential clinical utility of GCPS in stage II patients treated with surgery only. A time stamp protocol (**Figure S12**) was developed before processing of this final cohort. We subsequently developed a refined second-generation GCPS (GCPS-g2) (the final gene set) by analyzing the combined stage II cohorts from the second and third phases of the study.

Gene expression profiling using whole genome-DASL assay {#s2a}
-------------------------------------------------------

Before each gene profiling experiment, tissue samples were randomly allocated to different batches stratified by surgery time (before 2000 vs. after 2000) and tumor size (≤5 cm vs \>5 cm) to minimize any variations from the DNA quality. Total RNA was extracted from 2--4 sections of 4-µm thick FFPE sections from representative primary tumor blocks using the High Pure RNA Paraffin kit (Roche Diagnostic, Mannheim, Germany) after removing non-tumor elements by manual macrodissection guided by hematoxylin and eosin stained slides. WG-DASL assay was performed using 200 ng of RNA following the manufacturer\'s instruction [@pone.0090133-Bibikova1]. For nCounter assay, 200 ng of total RNA was hybridized with the custom designed code set of 800 genes for 18 hours at 65°C and processed according to manufacturer\'s instruction [@pone.0090133-Geiss1]. The data were normalized to average expression levels of 48 internal reference genes selected from microarray experiment. The detailed description of the discovery phase using WG-DASL assay is provided in **[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 3**. The comparability in DNA quality of FFPE tissue and fresh frozen tissues using DASL assay was published previously [@pone.0090133-Hoshida1], [@pone.0090133-Fan1].

Prognostic model building and validation {#s2b}
----------------------------------------

The algorithm for n-Counter-based assay development for clinical utility based on WG-DASL is provided in **[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Sections 4--6**. We used the gradient lasso algorithm to fit a prediction model based on Cox\'s proportional hazards model for DFS using the probes with marginal p value\<0.01 (**[Figure S2 in File S1](#pone.0090133.s001){ref-type="supplementary-material"}**) [@pone.0090133-Sohn1]. We used leave one out cross validation with de novo discovery at each leave one out step to assess the performance of the prognostic model within the discovery cohort. Optimal cut-point was determined by creating a plot for p-values for each cut-point for the prognostic score. For validation study, a priori defined algorithm and cut-point values were used. The validation method for GCPS is outlined in **[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 7**.

Results {#s3}
=======

Microarray gene expression profiling of GC patients treated with adjuvant chemoradiotherapy (phase 1) {#s3a}
-----------------------------------------------------------------------------------------------------

We performed gene expression profiling of FFPE from the discovery cohort of 520 cases of stage IB--IV GC treated with standard chemoradiotherapy after curative resection using the WG-DASL assay ([**Figure 1**](#pone-0090133-g001){ref-type="fig"}). Among them, 432 samples passed RNA quality control (GEO database GSE 26253) (**[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 3**). The primary end point was DFS. Univariate analysis identified 369 probes that were significantly associated with disease-free survival at p\<0.01 without adjustment for other clinical variables (**[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 3d**). Next, gradient Lasso was used to develop a prognostic algorithm to predict recurrence (**[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 3e**). The leave-one-out cross-validation (LOOCV) procedure with *de novo* discovery of prognostic genes and the building of a prognostic algorithm at each step was used to examine the robustness of the prognostic algorithm. According to prognostic gene signatures (26 genes, **[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 3f**) and pathologic stages (localized vs. advanced), 432 patients were categorized into the following groups: low-risk and stage IB/II (N = 145; 5-year DFS, 84.8%), high-risk and stage IB/II (N = 90; 5-year DFS, 61.1%), low-risk and stage III/IV (N = 83; 5-year DFS, 48.9%), and high-risk and stage III/IV (N = 114; 5-year DFS, 36.9%) ([**Figure 2**](#pone-0090133-g002){ref-type="fig"}). As an ad-hoc analysis, we tested this gene signature using gene expression profiling data from the Singapore patient cohort (N = 199) to minimize any inherent bias from a single institution cohort [@pone.0090133-Tan1]. In the external patient cohort, the gene signature was able to separate the high-risk group (N = 100) from the low-risk group (N = 99) for recurrence with statistical significance (p\<0.00001; hazard ratio (HR), 2.3; 95% CI, 1.62--3.28) ([**Figure 2**](#pone-0090133-g002){ref-type="fig"}). These data suggest the main clinical utility of gene expression profiling of GC in the identification of high-risk patients among stage II patients (low vs. high risk stage IB/II, 84.8% vs. 61.1%; low vs. high risk stage III/IV, 48.9% vs. 36.9%). Therefore, for the development of clinical assay and validation, we focused on developing a gene-set which can robustly predict recurrence in stage II patients.

![Kaplan-Meier curves for high risk and low risk groups classified by leave one out cross validation procedure.\
HR denotes hazard ratio and p-value is calculated from 100 permutations. (A) all stage patients, high vs low risk; (B) according to stage and risk groups; (C) External validation of the initial gene expression profiling.](pone.0090133.g002){#pone-0090133-g002}

Development of Gastric Cancer Prognostic Score (GCPS) for stage II GC using the nCounter assay (phase 2) {#s3b}
--------------------------------------------------------------------------------------------------------

We custom designed an nCounter probe set comprised of candidate prognostic genes from WG-DASL microarray data (phase 1), as well as known cancer genes, kinase genes, and G protein-coupled receptor genes. To address the variability problem in the integrity of RNA molecules in archived FFPE due to pre-analytical variables, such as fixation time and age of the blocks, we applied within-sample normalization using a set of 48 internal reference genes selected from microarray data based on minimum variation across cases and lack of association with prognosis (**[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 4**). Correlation between hazard ratios of prognostic genes based on nanostring and WG-DASL are provided in **[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 4b**, and **[Figure S3 in File S1](#pone.0090133.s001){ref-type="supplementary-material"}**.

We profiled 186 stage II patients from the discovery set. After assessing the robustness of prognostic algorithms built by gradient LASSO through LOOCV, we applied gradient LASSO to all 186 patients and identified 8 genes (LAMP5, CDC25B, CDK1, CLIP4, LTB4R2, MATN3, NOX4, and TFDP1) that in combination provided robust prognostic information ([**Table 1**](#pone-0090133-t001){ref-type="table"}). The GCPS was then developed as a linear combination of the Cox regression estimates and normalized expression levels of these 8 genes. The cut-point analysis demonstrates that the GCPS was most robust in identifying 25% of patients with worst outcomes (**[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 4**). We chose a cut-point of 0.2205 for prospective validation in the independent validation cohort.

10.1371/journal.pone.0090133.t001

###### List of genes that constitute Gastric Cancer Prognostic Score and their Cox regression estimates used to calculate the score.

![](pone.0090133.t001){#pone-0090133-t001-1}

  Gene Symbol                             Chromosomal location                                            Gene Name                                             Cox regression estimate
  -------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------- -------------------------
  LAMP5(BAD-LAMP, C20orf103)                     20p12                              Lysosomal-associated membrane protein family, member 5                              0.0636
  CDC25B                                         20p13                                   Cell division cycle 25 homolog B (S. pombe)                                    −0.0175
  CDK1                                          10q21.1                                           Cyclin-dependent kinase 1                                             −0.1005
  CLIP4 (UBASH3A, TULA, STS-2, TULA-1)           2p23.2          CAP-GLY domain containing linker family, member 4; Suppressor of T cell receptor signaling-2           0.4822
  LTB4R2                                      14q11.2-q12                                          Leukotriene B4 receptor                                              −0.3950
  MATN3                                         2p24-p23                                                 Matrillin 3                                                    0.2982
  NOX4                                        11q14.2-q21                                              NADPH oxidase 4                                                  0.0288
  TFDP1                                          13q34                                            Transcription factor Dp-1                                             −0.2886

Validation of GCPS and its predefined cut-point in stage II GC patients treated with chemoradiotherapy (phase 3) {#s3c}
----------------------------------------------------------------------------------------------------------------

To avoid the potential over-fitting issue associated with cross-validation [@pone.0090133-Simon1], we validated GCPS with the fixed algorithm and cut-points in an independent patient cohort that was not used in gene discovery. The clinical and pathological features of 216 stage II patients from the validation set were similar to those from the discovery cohort (**[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 6**, and **[Figures S4--6 in File S1](#pone.0090133.s001){ref-type="supplementary-material"}**). When we applied GCPS-g1 to the validation set, the risk score distribution was very similar, suggesting the robust analytical performance of the assay (**[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 7a**, and **[Figure S7 is File S1](#pone.0090133.s001){ref-type="supplementary-material"}**). The predefined cut-point (0.2205) for GCPS-g1 classified 22.7% of tumors from the validation set as the high-risk group. The Kaplan Meier estimate of 5-year DFS for the high-risk patients was 58.6%, compared to 85.4% for the low-risk patients (HR for recurrence, 3.16; p = 0.00004) ([**Figure 3**](#pone-0090133-g003){ref-type="fig"}). GCPS was significant in both intestinal- and diffuse- type GCs, as shown in [Figure S8 in File S1](#pone.0090133.s001){ref-type="supplementary-material"} (**[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 7b**). The multivariate analysis further shows that GCPS-g1 provided additional prognostic information, besides other known factors such as Lauren classification, differentiation grade, age, and surgery type (HR, 3.027; p = 0.00016; [**Table 2**](#pone-0090133-t002){ref-type="table"}). Therefore, GCPS may be used to identify stage II patients who remain at high risk even after standard adjuvant chemoradiotherapy and who have similar risk of recurrence as stage III patients.

![(A) DFS of stage 2 patients according to GCPS.\
(B) DFS of stage 2 patients treated with surgery according to GCPS.](pone.0090133.g003){#pone-0090133-g003}

10.1371/journal.pone.0090133.t002

###### Multivariate Cox regression analysis results on the validation set (N = 216).

![](pone.0090133.t002){#pone-0090133-t002-2}

                                                           Hazard ratio   P-value
  ------------------------------------------------------- -------------- ---------
  GCPS (low vs high-risk)                                     3.027       0.00016
  LAUREN (intestinal vs diffuse)                              0.541       0.18000
  WHO (W/D∼M/D vs P/D[\*](#nt101){ref-type="table-fn"})       2.491       0.07600
  AGE (65\< = vs 65\>)                                        1.496       0.19000
  Surgery types (subtotal vs total gastrectomy)               1.121       0.71000

\*W/D, well differentiated; M/D, moderately differentiated; P/D, poorly differentiated.

GCPS as a prognostic factor for stage II GC patients treated with surgery only based on a prospectively designed protocol (phase 4) {#s3d}
-----------------------------------------------------------------------------------------------------------------------------------

The review of the clinical database identified 306 patients who did not receive postoperative treatment based on shared decision between physicians and patients (**[File S1](#pone.0090133.s001){ref-type="supplementary-material"}, Section 1, [Table S1 in File S1](#pone.0090133.s001){ref-type="supplementary-material"}**). These patients were subjected to exploratory analyses for assessing the prognostic role of GCPS in patients treated with surgery only and testing the hypothesis that the benefit from chemoradiotherapy is limited in high-risk patients defined by GCPS. For this step, we developed GCPS-g2 (**[Table S8 in File S1](#pone.0090133.s001){ref-type="supplementary-material"}**), the second-generation GCPS, by analyzing all stage II cases from phases 2 and 3 to maximize the sample size. We prospectively tested the predefined GCPS-g2 algorithm and cut-point as described in the time stamp protocol (**[Figure S12 in File S1](#pone.0090133.s001){ref-type="supplementary-material"}**). The GCPS-g2 predicted recurrence in 300 stage II tumors with a hazard ratio of 2.131 (95% CI, 1.428--3.180; p = 0.00021) (HR, 3.16) (**[Figure S9 in File S1](#pone.0090133.s001){ref-type="supplementary-material"}**). To minimize the possibility of over-fitting of the algorithm to chemoradiotherapy-treated patients, we also tested the GCPS-g1, which was previously validated in the chemoradiotherapy-treated cohort, in surgery alone cohort (**[Figure S10 in File S1](#pone.0090133.s001){ref-type="supplementary-material"}**). The hazard ratio for GCPS-g1 (HR, 1.77; 95% CI, 1.18--2.67; p = 0.0053) is similar to that for GCPS-g2 ([**Figure 3**](#pone-0090133-g003){ref-type="fig"}). Therefore, the GCPS robustly predicted recurrence in stage II GC with or without postoperative treatment. Based on this data, it can be speculated that high-risk stage II patients defined by GCPS did not gain a tremendous benefit from chemoradiotherapy.

Expression of adverse prognostic genes in tumor microenvironments {#s3e}
-----------------------------------------------------------------

In all 3 stage II cohorts included in this study, increased expression levels of 4 genes from GCPS (NOX4, LAMP5, MATN3, and CLIP4) were associated with poor prognosis. Since the known functions of these genes suggest their expression in microenvironments rather than actual tumor cells, we performed the nCounter assay for microdissected tumors versus stromal components from 4 representative high-risk tumors (**[Figure S11 in File S1](#pone.0090133.s001){ref-type="supplementary-material"}**). The expression of these genes was significantly higher in stromal components, compared to epithelial cancer cells, with NOX4 showing the most pronounced differences (p = 0.04).

Discussion {#s4}
==========

In an initial discovery phase, we performed WG-DASL in all stage GC patients. Then, based on the WG-DASL data, we observed that the segregation of high risk group from low risk group was most significant in early stage Ib/II patients (low vs. high risk stage IB/II, 84.8% vs. 61.1%; low vs. high risk stage III/IV, 48.9% vs. 36.9%). Therefore, for the development of clinical assay and validation, we focused on developing a gene-set which can robustly predict recurrence in stage II patients. We developed and validated a prognostic algorithm for gastric cancer, GCPS, which can robustly identify high-risk groups for recurrence among stage II patients. GCPS, developed using the nCounter platform, showed the robust performance in FFPE samples. In addition, the inclusion of internal reference genes allowed the application of GCPS to individual patients. Therefore, we suggest that GCPS can be readily applied to routine clinical use. The GCPS of 8 genes (LAMP5, CDC25B, CDK1, CLIP4, LTB4R2, MATN3, NOX4, and TFDP1) were discovered and validated in over 700 stage II GC patients. We found that the GCPS identified high-risk GC patients for recurrence regardless adjuvant treatment and that high-risk stage II GC patients showed similar DFS to stage III patients. Notably, the GCPS predicted recurrence of both Lauren types (diffuse or intestinal) (**[Figure S8 in File S1](#pone.0090133.s001){ref-type="supplementary-material"}**).

Our data clearly demonstrate the presence of molecular heterogeneity in GC, which was associated with clinical outcomes but independent of clinicopathologic staging information. Our data indicate that stage IB/II patients had very poor prognosis when their tumors expressed poor-risk gene signatures. There was a difference of 23.7% in 5-year DFS between high-risk and low-risk gene signatures in stage IB/II patients, and 5-year DFS of high-risk stage IB/II patients was below 60%, despite the use of adjuvant chemoradiotherapy ([**Figure 1**](#pone-0090133-g001){ref-type="fig"}). Therefore, it may be necessary to prospectively design a trial to question whether chemoradiotherapy is required for stage IB/II patients with low-risk gene expression profiles. In order to minimize any potential bias from variations in clinical practice or surgery at a single center, we performed an ad hoc external validation of the signature to validate the signature. As shown in the [Results](#s3){ref-type="sec"}, the signature consistently predicted recurrence in Singapore cohort.

Among the 8 final GCPS genes (LAMP5, CDC25B, CDK1, CLIP4, LTB4R2, MATN3, NOX4, and TFDP1), CDC25B and CDK1, which are known to be associated with cell proliferation, were found to correlate with favorable prognosis (negative Cox regression estimates in [Table 2](#pone-0090133-t002){ref-type="table"}). Notably, a similar trend has been observed for colon cancer by a gene expression assay [@pone.0090133-Allegra1], [@pone.0090133-ClarkLangone1]. These findings may reflect the differentiation status of these tumor cells, since normal gastric and colon mucosal epithelial cells have high turnover rates. TFDP1 encodes the transcriptional factor DP-1, which acts as a positive regulator of the G1/S transition during the cell cycle [@pone.0090133-Yasui1], [@pone.0090133-Yasui2]. Particularly in hepatocellular carcinoma, TFDP1 overexpression was substantially associated with disease progression [@pone.0090133-Yasui1]. Since the scope of this current study does not include the functional study of these genes, their biological significance should be investigated in future studies. Recently, Cho *et al.* has performed the largest gene expression profiling in 213 GC patients using fresh frozen tissues [@pone.0090133-Cho1]. They identified 6 prognostic genes (CTNBB1, EXOCS3, TOP2A, LBA1, CCL5, and LZTR1) for patient survival after curative resection. However, to the best of our knowledge, GCPS is the only gene set which has now been validated in more than 700 stage II GC patients, regardless Lauren classification (diffuse or intestinal), a known prognostic factor, or adjuvant treatment.

In conclusion, with the use of a multistep approach, we developed 8-gene GCPS, which was able to robustly identify high-risk stage II GC patients for recurrence after surgery regardless of adjuvant treatment. Currently, with the ongoing ARTIST-II trial (NCT\#01761461), we plan to validate our GCPS in a prospectively designed phase III trial.
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